Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Shortly after his proposal, Doctor James Blundell, a British obstetrician, performed a series of human blood transfusions in 1818 for the treatment of postpartum hemorrhage.
Intravenous technology was first published in 1883 by Doctor Thomas Latta during a cholera epidemic in Britain.
The standard IV use of saline solutions did not begin until 1902.
Redonnet made the first IV barbiturate, Somnifen, in 1920.
Until the 40s, IVs were only implemented by Doctors, but in 1940, Massachusetts General Hospital allowed a nurse to administer IV therapy, a process nurses had previously only assisted with.
Methohexital, a shorter-acting barbiturate with central nervous system-stimulating properties, was introduced in 1956 and remains a popular anesthetic for electroconvulsive therapy (ECT).
Price suggested in 1960 that thiopental redistribution from brain to muscle, rather than to fat, explained the rapid awakening from thiopental.
In December 1998 Fresenius acquired the international infusion business of Pharmacia & Upjohn (Kabi).
When Doctor Meyer passed away, his patients sought IV Therapy with another Baltimore physician Doctor Gaby, who documented and published this treatment in 2002, and named it Meyer’s Cocktail, in honor of Doctor Meyer.
White, P. (2014). A History of Intravenous Anesthesia.
The Origins of Intravenous Fluids – http://blogs.discovermagazine.com/bodyhorrors/2016/05/31/intravenous-fluids-cholera/#.Wrkk0NPwZ24
Fresenius Kabi AG © July 2022
Rate how well INTRAV lives up to its initial vision.
Do you work at INTRAV?
Is INTRAV's vision a big part of strategic planning?
Zippia gives an in-depth look into the details of INTRAV, including salaries, political affiliations, employee data, and more, in order to inform job seekers about INTRAV. The employee data is based on information from people who have self-reported their past or current employments at INTRAV. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by INTRAV. The data presented on this page does not represent the view of INTRAV and its employees or that of Zippia.
INTRAV may also be known as or be related to INTRAV.